Cemiplimab: First Global Approval

Markham, A; Duggan, S

Markham, A (reprint author), Springer, Private Bag 65901, Auckland 0754, New Zealand.

DRUGS, 2018; 78 (17): 1841

Abstract

Cemiplimab (LIBTAYO (R); cemiplimab-rwlc), a human programmed death receptor-1 (PD-1) monoclonal antibody that binds to PD-1 and blocks its interactio......

Full Text Link